MASTER INVESTOR SHOW 2025

Drew Burdon

Partner, EQT Life Sciences, EQT Group

Drew Burdon, PhD, MBA, is a Partner within EQT, and works within the EQT Life Sciences business line. Drew’s primary responsibility within EQT LS is to invest in unlisted securities, and Drew has a specific focus on the health economics funds, targeting Med Tech, Digital and Diagnostic investment opportunities. Drew has been involved in many investment opportunities during his EQT LS career and Drew currently holds Board Director positions for 5 companies across the UK and Europe.

Prior to joining EQT LS in 2019, Drew had a 13-year career at Smith & Nephew, performing in a range of increasingly senior roles across a number of functional areas including R&D, commercial strategy, marketing (including product launch) and business development. Immediately prior to joining EQT LS, Drew was a Director of Corporate Development with Smith & Nephew, where Drew developed and transacted share and asset acquisitions, divestments and made equity investments on behalf of the company. Of particular note, Drew led the acquisitions of Rotation Medical (US) and Ceterix Orthopaedics (US). Additionally, Drew led equity investments in Trice Medical (US) and Leaf Healthcare (US) and held Board observer positions with Leaf Healthcare (US) and OrthoSpace (Israel).

Prior to joining Smith & Nephew, Drew completed a three-year postdoctoral fellowship with Cancer Research UK, investigating the use of adenoviral vectors and re-targeting proteins for the treatment of bladder and other urological cancers. Drew’s academic credentials include a BSc (Hons) in Medical Biochemistry and a PhD in Cell and Molecular Biology (both from the University of Leicester, UK), as-well as an Executive MBA, with a focus on strategy, financial strategy and creativity, innovation and change, from the Open University (UK).